Abstract
Sodium glucose cotransporter 2 inhibitors are increasingly being recognized for renal protective effects that are largely independent of hemoglobin A1c-lowering or glucosuria-related endpoints. Accordingly, there is growing interest in potential renal benefits with sodium glucose cotransporter 2 inhibitors in nondiabetic patients to take advantage of natriuresis-mediated effects on blood pressure, proteinuria, and renal function. In this issue of Kidney International, Zhang et al. report renoprotective effects with the sodium glucose cotransporter 2 inhibitor lusogliflozin in an ischemia-reperfusion injury model under nondiabetic conditions, thereby providing important mechanistic insights into the use of these agents in chronic kidney disease.
Citations
Aug 3, 2019·Diabetes Care·Daniël H van RaalteDavid Cherney
Apr 9, 2020·Diabetes, Obesity & Metabolism·Vikas S SridharDavid Z I Cherney
Apr 9, 2020·Diabetes, Obesity & Metabolism·Jonatan Barrera-Chimal, Frédéric Jaisser
Oct 22, 2019·Endocrine Reviews·Yuliya LytvynDavid Z I Cherney
Sep 15, 2020·Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia·Vikas S SridharDavid Z Cherney
Oct 3, 2020·Expert Opinion on Drug Discovery·Chhanda Charan DantaShang-Zhong Xu
Aug 28, 2020·Frontiers in Pharmacology·Dyah Ari NugrahaningrumVivi Kasim
Oct 30, 2020·Canadian Journal of Kidney Health and Disease·Adeera LevinRita S Suri
Dec 31, 2020·Clinical Journal of the American Society of Nephrology : CJASN·Min ZhaoHuilin Tang
May 1, 2021·Life·Sungjin Chung, Gheun-Ho Kim
Aug 14, 2021·KI Reports·Hongyan LiuDavid Z I Cherney
Jun 3, 2021·Current Opinion in Nephrology and Hypertension·Mohanad AlmaimaniDavid Z I Cherney
Aug 3, 2021·Diabetes, Obesity & Metabolism·David Z I CherneyRajiv Agarwal
Sep 11, 2021·Current Opinion in Nephrology and Hypertension·Trond G Jenssen
Nov 16, 2021·Diabetes, Obesity & Metabolism·Ajay ChaudhuriPradeep Arora